This activity was originally broadcast live as a satellite symposium held in conjunction with HOPA 2022.
Program Description
Diffuse large B-cell lymphoma (DLBCL) is an aggressive form of non-Hodgkin lymphoma (NHL). Frontline treatment includes the monoclonal antibody rituximab in addition to systemic chemotherapy. In those patients with disease relapsed or refractory (R/R) to standard of care, treatment is more challenging, as many patients relapse after salvage chemotherapy and autologous stem cell transplant. Newer therapies, including antibody drug conjugates (ADCs) and chimeric antigen receptor (CAR) T-cell therapies, are changing the treatment of R/R DLBCL. This activity will feature a multidisciplinary panel, discussing nuances of ADCs and CAR T-cell therapies and how these treatments fit into the treatment paradigm of patients with R/R DLBCL.
Target Audience: Oncology pharmacists
Type of Activity: Application
Release date: April 15, 2022
Expiration date: April 15, 2023
Time to complete activity: 1.0 hours
Fee: Free
Educational Objectives
At the completion of this activity, participants will be able to:
- Explore the role of antibody-drug conjugates (ADCs) and chimeric antigen receptor (CAR) T-cell therapy in the treatment paradigm of relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL).
- Compare unique characteristics of ADCs and CAR T-cell therapies for the treatment of R/R DLBCL.
- Construct a treatment plan that incorporates an ADC or CAR T-cell therapy for a patient with R/R DLBCL
Nilanjan Ghosh, MD, PhD
Chief, Lymphoma Division
Professor of Medicine and Oncology
Levine Cancer Institute
Charlotte, NC
Kelly Valla, PharmD, BCOP
Columbia, MD
Amy Goodrich, CRNP
Nurse Practitioner
Research Associate
Johns Hopkins Kimmel Cancer Center
John Hopkins University
Baltimore, MD
Jane de Lartigue, PhD
Medical Writer
Scientific Medical Writer
JLSC (Jane de Lartigue Scientific Communications)
Pharmacy Times Continuing Education™ is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 1.0 contact hours (0.10 CEU) under the ACPE universal activity number 0290-0000-22-166-H01-P. The activity is available for CE credit through April 15, 2023.
Instructions for Completing the Activity and Receiving CPE Credit
To receive CPE credit, participants must complete the pretest, watch the symposium in its entirety, complete the posttest, and complete the online activity evaluation. After successful completion of the online activity evaluation, you can submit your credit to CPE Monitor. You may view your credit within 48 hours at www.mycpemonitor.net. All participants must request credit before the activity expiration date. CE credit will not be issued after this date.
Disclosures
Nilanjan Ghosh, MD, PhD has the following relevant financial relationships with commercial interests to disclose:
- Grant/Research Support: Pharmacyclics, TG Therapeutics, Genentech/Roche, BMS, Morphosys, Kite/Gilead, AbbVie
- Consultant: Seattle Genetics, TB Therapeutics, AstraZeneca, Pharmacyclics/Janssen, BMS, Gilead/Kite, Incyte, Novartis, Roche/Genentech
- Speaker’s Bureau: AstraZeneca Pharmaceuticals, Janssen, BMS, Kite/Gilead
Kelly Valla, PharmD, BCOP has the following relevant financial relationships with commercial interests to disclose:
- Speaker’s Bureau: BeiGene
The following contributors have no relevant financial relationships with commercial interests to disclose:
Faculty
Amy Goodrich, CRNP
Jane de Lartigue, PhD
Pharmacy Times Continuing Education™ Planning Staff—Jim Palatine, RPh, MBA; Maryjo Dixon, RPh; Meg Taylor, PharmD, CPP; Kylie Ferrentino; Susan Pordon; Brianna Winters; and Chloe Taccetta
An anonymous peer reviewer was used as part of content validation and conflict resolution. The peer reviewer has no relevant financial relationships with commercial interests to disclose.
Medical reviewer Samantha Price, PharmD, BCOP, has the following relevant financial relationships with commercial interests to disclose:
Consultant (spouse): Kite Pharma, Epizyme, MorphoSys, Amgen, Kymera, AbbVie, BeiGene, AstraZeneca, Pfizer, ADC Therapeutics, TG, Novartis, Karyopharm
Educational Disclaimer
CPE activities are offered solely for educational purposes and do not constitute any form of professional advice or referral. Discussions concerning drugs, dosages, and procedures may reflect the clinical experience of the author(s) or they may be derived from the professional literature or other sources and may suggest uses that are investigational in nature and not approved labeling or indications. Participants are encouraged to refer to primary references or full prescribing information resources.
For questions about this internet CPE activity, please contact:
[email protected]
Privacy Policy and Terms of Use Information:
www.pharmacytimes.org/terms